Goodwin Procter advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals. Celexor Bio is being formed in connection...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as legal counsel to ReWalk, and Wilson Sonsini acted as legal counsel to AlterG. ReWalk Robotics Ltd. (Nasdaq: RWLK) announced closing of the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Globus Medical on the deal. Globus Medical (NYSE: GMED) announced its definitive agreement with NUVASIVE (NASDAQ: NUVA) to combine in an all-stock transaction. Under...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Societal CDMO, Inc. on the deal. Societal CDMO, Inc., a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised iECURE on the deal. iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Larimar Therapeutics, Inc. on the deal. Larimar Therapeutics, Inc. (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised TELA Bio on the deal. TELA Bio announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Center for Breakthrough Medicines on the deal. Center for Breakthrough Medicines (CBM) has struck a landmark collaboration agreement with the University of Pennsylvania’s...
You must be a Standard 1 Year member to access this content.
Troutman Pepper advised Century Therapeutics on the deal. Century Therapeutics (NASDAQ: IPSC) has announced a research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY)...
You must be a Standard 1 Year member to access this content.
Simpson Thacher represented SK Group on the deal while Troutman Pepper Hamilton Sanders advised Center for Breakthrough Medicines. SK Inc. announced its $350 million investment in The...
You must be a Standard 1 Year member to access this content.
